Nkarta will hold a webcast on November 9, 2026, at 8:00 a.m. ET to review initial clinical data from its Ntrust program evaluating NKX019 in patients with myositis and systemic sclerosis. The data is being presented at the American College of Rheumatology (ACR) Convergence 2026. Nkarta is a clinical-stage biotechnology company developing engineered natural killer cell therapies to treat autoimmune diseases.
